The State of Weight-Loss Drugs
- Forfatter
- Afsnit
- 1787
- Udgivet
- 1. mar. 2025
- Forlag
- 0 Anmeldelser
- 0
- Afsnit
- 1787 of 2000
- Længde
- 30M
- Sprog
- Engelsk
- Format
- Kategori
- Økonomi & Business
$150 billion. That’s how much some experts estimate weight-loss drugs could bring in in sales within the next five years.
Motley Fool analyst Karl Thiel joins Ricky Mulvey to check in on the GLP-1 landscape. They also discuss: - How weight-loss drugs actually work, and how big-name prescriptions differ from each other. - What investors need to know about Ozempic and Mounjarno’s patent cliffs. - The scenarios in which Novo Nordisk and Eli Lilly are actually undervalued.
Companies discussed: LLY, NOVO, HIMS, PFE, RHHBY, VKTX, GPCR, ISRG
Host: Ricky Mulvey Guest: Karl Thiel Producer: Mary Long Engineer: Rick Engdahl
Learn more about your ad choices. Visit megaphone.fm/adchoices
Other podcasts you might like ...
- The Journal.The Wall Street Journal & Spotify Studios
- The Can Do WayTheCanDoWay
- HW News Business Tit-BitsHW News Network
- 1,5 graderAndreas Bäckäng
- Self-Compassionate ProfessorPhD
- Networth and Chill with Your Rich BFFVivian Tu
- Don't Be SourMaxx Chewning
- Mark My Words PodcastMark Homer
- EGO NetCastMartin Lindeskog
- The Pathless Path with Paul MillerdPaul Millerd
- The Journal.The Wall Street Journal & Spotify Studios
- The Can Do WayTheCanDoWay
- HW News Business Tit-BitsHW News Network
- 1,5 graderAndreas Bäckäng
- Self-Compassionate ProfessorPhD
- Networth and Chill with Your Rich BFFVivian Tu
- Don't Be SourMaxx Chewning
- Mark My Words PodcastMark Homer
- EGO NetCastMartin Lindeskog
- The Pathless Path with Paul MillerdPaul Millerd
